Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
Child
Child, Preschool
Female
France
/ epidemiology
Genotype
Hospitalization
Humans
Infant
Infant, Newborn
Intensive Care Units
Male
Middle Aged
Odds Ratio
Retrospective Studies
SARS-CoV-2
/ classification
Severity of Illness Index
Young Adult
Coronavirus disease 2019
Marseille
Mutation
N501Y
Severe acute respiratory syndrome coronavirus 2
Variant
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
03
03
2021
revised:
11
05
2021
accepted:
15
05
2021
pubmed:
28
5
2021
medline:
16
10
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
To compare the clinical and epidemiological aspects associated with different predominant lineages circulating in Marseille from March 2020 to January 2021. In this single-centre retrospective cohort study, characteristics of patients infected with four different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were documented from medical files. The outcome was the occurrence of clinical failure, defined as hospitalization (for outpatients), transfer to the intensive care unit (inpatients) and death (all). A total of 254 patients were infected with clade 20A (20AS), 85 with Marseille-1 (M1V), 190 with Marseille-4 (M4V) and 211 with N501Y (N501YV) variants. 20AS presented a bell-shaped epidemiological curve and nearly disappeared around May 2020. M1V reached a very weak peak, then disappeared after six weeks. M4V appeared in July presented an atypical wave form for 7 months. N501YV has only recently appeared. Compared with 20AS, patients infected with M1V were less likely to report dyspnoea (adjusted odds ratio (OR) 0.50, p 0.04), rhinitis (aOR 0.57, p 0.04) and to be hospitalized (aOR 0.22, p 0.002). Patients infected with M4V were more likely to report fever than those with 20AS and M1V (aOR 2.49, p < 0.0001 and aOR 2.30, p 0.007, respectively) and to be hospitalized than those with M1V (aOR 4.81, p 0.003). Patients infected with N501YV reported lower rate of rhinitis (aOR 0.50, p 0.001) and anosmia (aOR 0.57, p 0.02), compared with those infected with 20AS. A lower rate of hospitalization was associated with N501YV infection compared with 20AS and M4V (aOR 0.33, p < 0.0001 and aOR 0.27, p < 0.0001, respectively). The four lineages have presentations that differ from one another, epidemiologically and clinically. This supports SARS-CoV-2 genomic surveillance through next-generation sequencing.
Identifiants
pubmed: 34044152
pii: S1198-743X(21)00270-6
doi: 10.1016/j.cmi.2021.05.029
pmc: PMC8142822
pii:
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1516.e1-1516.e6Informations de copyright
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Travel Med Infect Dis. 2020 Jul - Aug;36:101632
pubmed: 32205269
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
J Clin Virol. 2021 Jul;140:104868
pubmed: 34029990
Lancet Infect Dis. 2021 Sep;21(9):1246-1256
pubmed: 33857406
Travel Med Infect Dis. 2021 Mar-Apr;40:101980
pubmed: 33535105
Euro Surveill. 2021 Mar;26(11):
pubmed: 33739254
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478621
Source Code Biol Med. 2008 Dec 16;3:17
pubmed: 19087314
Nature. 2021 May;593(7858):270-274
pubmed: 33723411